AN2 Therapeutics, Inc. (ANTX)
$
1.15
+0.03 (2.61%)
Key metrics
Financial statements
Free cash flow per share
-1.1767
Market cap
31.4 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
31.9565
Income quality
0.9498
Average inventory
0
ROE
-0.4797
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases. Incorporated in 2017 and headquartered in Menlo Park, California, the company is working on epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease. The financial data pertains to the fiscal year 2024 and during this period, the company reported selling, general, and administrative expenses of $14,066,000.00 indicating its operational overhead costs. Additionally, the weighted average number of diluted shares outstanding is 29,828,000.00 reflecting potential dilution effects, while the weighted average number of shares outstanding is 29,828,000.00 highlighting the company's shareholder base. The EBITDA ratio is 0.00 underscoring the company's operational efficiency. The stock is affordable at $1.07 suitable for budget-conscious investors. With a market capitalization of $31,425,130.00 the company is classified as a small-cap player, which suggests a unique position within the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, driving innovation and growth. Moreover, the stock has a low average trading volume of 207,701.00 indicating lower market activity, which may appeal to certain investment strategies focused on niche opportunities.
Is AN2 Therapeutics, Inc. (ANTX) a good investment?
Investing in AN2 Therapeutics, Inc. (ANTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is AN2 Therapeutics, Inc. (ANTX)'s stock forecast?
Analysts predict AN2 Therapeutics, Inc. stock to fluctuate between $0.98 (low) and $1.68 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AN2 Therapeutics, Inc.'s market capitalization?
As of 2025-08-20, AN2 Therapeutics, Inc.'s market cap is $31,425,130, based on 27,326,200 outstanding shares.
How does AN2 Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., AN2 Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. pays dividends. The current dividend yield is 17.05%, with a payout of $0.66 per share.
How can I buy AN2 Therapeutics, Inc. (ANTX) stock?
To buy AN2 Therapeutics, Inc. (ANTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANTX. Place an order (Market, Limit, etc.).
What is the best time to invest in AN2 Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did AN2 Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.72 | Growth: -37.23%.
Where can I find AN2 Therapeutics, Inc.'s investor relations reports?
Visit https://www.an2therapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AN2 Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for AN2 Therapeutics, Inc. stock?
All-time high: $23.58 (2022-05-16) | All-time low: $0.87 (2024-08-09).
What are the key trends affecting AN2 Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
9 days ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has completed dosing the first single ascending dose cohort in its Phase 1 first-in-human clinical trial evaluating the safety, tolerability, and pharmacokinetics of oral AN2-502998 in healthy volunteers. AN2-502998 is a potentially curative drug candidate for chronic.
businesswire.com
a month ago
MENLO PARK, Calif. & GENEVA--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) today announced a collaboration to advance clinical development of AN2-502998, AN2's oral drug candidate in development for the treatment of chronic Chagas disease. Chagas disease is a life-threatening disease caused by the parasite Trypanosoma cruzi and affects 6 to 7 million people worldwide, including an estimated.
businesswire.com
2 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and recognized biothreat. The study, conducted under real-world conditions in acute hospital settings, evaluated patients receiving the current standard of care (SoC).
businesswire.com
3 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated that.
businesswire.com
3 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025. “As we look ahead to the remainder of 2025, we are poised to advance our pipeline leveraging our boron chemistry platform, which has the potential to address serious unmet needs of patients. We have high.
businesswire.com
5 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024. "Epetraborole demonstrated potential proof-of-concept in Phase 2, achieving nominal statistical significance on two patient-reported outcome measures in patients with treatment-refractory MA.
businesswire.com
6 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, wil.
businesswire.com
6 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monda.
businesswire.com
7 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Fou.
businesswire.com
9 months ago
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. Details of the events are as follows: 7th Annual Evercore HealthCONx Conference, December 3-5, 2024 Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corpo.
See all news
